

Figure S1. Pharmacological inhibition of GSK-3 with 9-ING-41 potentiates the effect of anticancer therapeutics in RCC cells. Relative cell proliferation was measured by MTS assay in RCC cell lines (A and B) KRCY and (C and D) KU19-20 treated with 9-ING-41 in combination with (A and C) targeted therapeutics (sorafenib, sunitinib, pazopanib and cabozantinib) or (B and D) autophagy inhibitors (chloroquine and bafilomycin) for 72 h as indicated. RCC, renal cell carcinoma.

